Preserving and rejuvenating donor organs using ex vivo perfusion
12 July 2017, by Scott Behm

Surgeons examine the pulmonary vessels during a lung transplant performed in April 2017. Credit: Shawn Rocco

Each day, tens of thousands of patients on waiting lists across the United States await a simple phone call: one that says a match has been found and an organ is available for transplant. Despite a growing demand for donors, organ shortages continue to hinder many patients' chances in receiving their potentially life-saving call.

The organ shortage has impacted several transplant teams at Duke. Carmelo Milano, MD, Professor, Division of Cardiovascular and Thoracic Surgery, says part of the reason for the shortage is the method used to preserve organs while in transit from donor to recipient.

"Duke has performed over 1,000 heart transplants using cold static storage," says Dr. Milano, Heart Transplant Surgical Director. (That's a fancy term for a bag of ice.) "With this method, the heart is removed from the donor and cooled with a solution before it is transported, but lack of oxygen to the organ can cause graft failure."

Cold storage has been a staple of the transplant procedure for over 50 years. While this method is serviceable, it is far from ideal. Vital organs are sensitive to cold ischemia while stored on ice, as irreparable damage from a lack of oxygenated blood flow rapidly occurs. When a heart stops beating, or lungs stop breathing, the organ slowly dies.

Cold storage slows down the deterioration process but not entirely, and this race against the clock severely limits organ availability. The heart is particularly sensitive to cold ischemia. Consequently, Duke's range of potential donors for heart transplants has been limited to those east of the Mississippi, according to Dr. Milano.

The lung transplant team faces similar obstacles, says Matthew Hartwig, MD, Associate Professor, Division of Cardiovascular and Thoracic Surgery. Though the team has successfully transplanted lungs held in cold storage for longer than the conservative 4-hour window, Dr. Hartwig says doing so can create more complications. With such a small window of time, organ matches found a considerable distance away often go unused.

The Ice Age May Be Over

The most logical answer to the cold storage problem is also the most challenging: keep a transplanted organ in a near-physiologic state while outside of the body, perfused with blood, and limit the amount of time the organ is kept on ice.

Though the ability to keep an organ alive outside of the body may sound like something out of science fiction, perfusion systems make this a reality. The devices keep an organ as functional as possible after surgical removal, during a process known as "ex vivo perfusion." Rather than using ice, the device stores the organ at close to body temperature, causing less injury. Nutrient-rich blood taken from the donor filters through the organ, and the system allows close monitoring while the donated organ remains in a living state: beating, breathing, or producing bile, metabolizing glucose and balancing the blood's chemistry.

Several Duke teams are at the forefront of national clinical studies to examine the effectiveness of
these devices in transplant procedures.

Duke's cardiac transplant team has partnered with TransMedics, whose portable Organ Care System (OCS) allows the heart to be perfused while in transit from donor to recipient. Dubbed the "heart in a box," the device is sent with the procurement team to retrieve the heart, which is transported back to the transplant center.

The first successful surgery at Duke using an organ transported via the OCS was performed in July 2016. The surgery would not have been possible without the new system due to the distance the organ had to travel, says Dr. Milano. Since then, surgeons have performed eight more successful transplants using the OCS.

The lung transplant team has also had success using a device developed by XVIVO Perfusion, completing 25 successful transplants and enrolling more patients than any other center in the United States for the trial. Lungs are fragile organs at high risk for infection due to their role as a main filter of our outside environment. This fragility comes at a cost: the Organ Procurement and Transplantation Network reports only 1 in 4 donated lungs is viable for transplant.

Duke's trial with the XVIVO system focused specifically on lungs that initially would not have been accepted for transplant. Using a perfusion device allows the lungs to breathe without straining, making the organ stronger and healthier outside of the body.

The liver transplant team formed a third partnership with OrganOx. The manufacturer's metra device allows the donor's liver to be preserved for up to 24 hours prior to transplant. This clinical trial began in February of 2017.

"There are several benefits to using the device," explains Andrew Barbas, MD, Assistant Professor, Division of Abdominal Transplant Surgery. "We can access the metabolic activity of the liver and restore energy levels in liver cells. We can also assess which organs will function better after transplant."

This evaluation period prior to the transplant procedure can be critical to success, and perfusion devices offer the surgeon more breathing room to examine the organ fully before surgery begins.

Expanding the Donor Pool

Duke's transplant surgeons all say perfusion systems can increase the number of organs available. Longer preservation times allow organs to travel greater distances, offering a larger geographic area to search for matches.

But more important than geography is the ability to use "extended criteria organs," says Jacob Schroder, MD, Assistant Professor, Division of Cardiovascular and Thoracic Surgery.

"Extended criteria hearts have some feature that makes them imperfect—ventricular hypertrophy, minor coronary disease, advanced age of the donor, certain causes of death, or a long estimated
ischemic time," says Dr. Schroder. "The success rate for these hearts has traditionally been very low, but the OCS device allows us to take the ischemic time out of the question."

Whether heart, lung, or liver, when the threat of damage from cold storage is minimized, more organs become viable options for patients in need. To put it simply, Dr. Schroder explains that utilizing the OCS is the equivalent of transplanting an organ from a donor found in Raleigh, rather than farther away. It entails less risk, and more positive outcomes.

**The Future of Ex Vivo Perfusion**

Perfusion also raises an interesting question about the ability to rehabilitate organs while outside of the body: Is it possible to transplant an organ in a better condition than when it was procured?

Dawn Bowles, PhD, Assistant Professor, Division of Surgical Sciences, believes this may be a possibility. She has conducted biological therapy studies using pig hearts perfused in the TransMedics OCS.

"These devices answer questions about whether or not a heart can be rehabilitated while it is stored," says Bowles. "It is possible that we could fix some things that need fixing in a heart before it is transplanted."

While this type of therapy is still on the horizon, it highlights the potential of the new technology. Through a grant from the American Society of Transplant Surgeons, Dr. Barbas is using animal models to test the possibility of repairing damaged livers through perfusion.

Repairing organs ex vivo may be another solution to the organ shortage problem.

This potential application may already be a reality for lung transplants. Duke's next trial with United Therapeutics will test the use of what Dr. Hartwig calls an "organ hospital"—a centralized location where organs are rehabilitated before transplantation.

"This technology is still in its infancy, but I can see